OMEGA-3-FATTY ACID SUPPLEMENTATION TO PREVENT PRETERM BIRTH AMONG WOMEN AT RISK

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。早产仍然是导致非异常婴儿死亡和发病率的一个重要因素。在最近完成的一项每周注射17α-羟孕酮己酸酯(17P)的试验中，美国国家儿童健康与人类发展研究所(NICHD)母亲胎儿医学单位(MFMU)网络发现，这些治疗方法在预防反复早产方面非常有效。这项研究的目的是确定欧米茄-3，一种多不饱和脂肪酸营养补充剂，在注射17P的基础上，是否降低有风险的妇女的早产率。有过早产经历的妇女，在怀孕21周或之前接受产前护理的妇女有资格。女性将每周接受一次注射。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Preterm birth remains an essential component along the causal pathway for non-anomalous infant mortality and morbidity. In a recently completed trial of weekly injections of 17 alpha hydroxyprogesterone caproate (17P), the National Institute of Child Health and Human Development (NICHD) Maternal Fetal Medicine Unit (MFMU) Network found the treatments significantly beneficial in the prevention of recurrent preterm birth. The purpose of this study is to determine whether Omega-3, a polyunsaturated fatty acid nutritional supplement, in addition to injections of 17P decreases the rate of preterm birth in women at risk. Women who have had a previous preterm birth who appear for prenatal care on or before 21 weeks of gestation are eligible. Women will receive weekly injections.